Overview

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC.

Phase:

PHASE3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin